To share or not to share – What the general public thinks about global COVID-19 vaccine distribution

Authors: Matthias Klumpp[1], Ida G. Monfared[2]*, Sebastian Vollmer[2]

Affiliations:

[1]Georg-August-University of Göttingen, Department of Business Administration, Chair for Production and Logistics, Platz der Göttinger Sieben 3, 37073 Göttingen, Germany.

[2]Georg-August-University of Göttingen, Department of Economics, Centre for Modern Indian Studies, Waldweg 26, 37073 Göttingen, Germany.

*Corresponding author. Email: ida.gohardoustmonfared@uni-goettingen.de

Abstract: We conducted representative surveys among the adult population in Germany (n=1,003) and the United States (n=1,000) with discrete choice experiments and analytical hierarchy process items to elicit opinions about global COVID-19 vaccine distribution. Results unveil a high consent towards utilitarian or egalitarian distribution principles, prioritizing countries with weak health care systems and high numbers of current cases or deaths. This implies that the public in Germany and the United States has very well understood the global nature of the pandemic and how important sharing of resources and vaccines really is.

One-Sentence Summary: The people in Germany and the United States favor utilitarian or egalitarian distribution principles for global COVID-19 vaccine distribution.

Introduction

For the first time in history of humankind, a vaccine was developed *during* a global pandemic within a 12-months timeframe. Vaccine production resources are scarce and not matching demand given the economic and social burden of lockdown measures in each and every country worldwide at the same time – and this squeeze will continue until at least 2022. The situation regarding virus variants and possible refreshing shots due to declining vaccination protection over time make (re-)distribution decisions between countries even harder (*1*). These special circumstances bring about new and unexperienced questions regarding distribution fairness and rationale of scarce COVID-19 vaccine doses on a global scale (*2, 3*).

Scope of the Study

Getting access to COVID-19 vaccine doses shows a great disparity between countries across the globe. Some high-income countries (HICs) were able to secure substantial numbers of doses early on via either pre-order or in-country production and have managed to vaccinate a noticeable share of their population (*4*). However, some others, particularly low- and many middle-income countries (LMICs) have been left behind (*5*). These countries also carry a heavier burden in the pandemic as their healthcare systems are often fragile and inadequate to cope with the pressure leading to higher number of COVID-19 deaths as can be observed for example in Peru or South Africa (*6, 7*). Moreover, the emergence of new variants shows that HICs are not safe either, unless actions are taken globally (*8*). As evidence shows, it is only a matter of time until variants like Beta, Delta or Lambda find their way to HICs (*9*). There are various views around "vaccine nationalism" (*10*) and perhaps decision-makers in HICs could argue that they have a legitimate fear of public backlash if they share more vaccine doses with countries in need (*11*). The present study aims to find if such attitude exists and provides answer to the question that to what extent vaccine nationalism can be detected in the public view. For this purpose, a representative survey of the general public in Germany (n=1,003) and the United States (n=1,000) was conducted, controlling for regional distribution, gender, age, employment status, shares of population that have been vaccinated, and education levels. The four main

study instruments (in the order of appearance in the survey) were a) an Analytical Hierarchy Process (AHP) measuring the relative importance of four principles ("equal access for all", "medical urgency", "free market rules apply", and "production contribution") based on egalitarian, utilitarian, libertarian, and merits grounds, respectively; b) a discrete decision making experiment asking respondents to divide a hypothetical 100 Million doses of vaccines between two countries A and B with their profiles resembling a high-income and low-income country, respectively, first under general veil of ignorance, then in a scenario where one of their vulnerable family members was waiting in Country A and then when the respondents him/herself would be waiting to be vaccinated in Country A (*12*); c) a scale item question asking respondents level of agreement to wait for their own vaccine for 3 months so that people in countries with various characteristics could be vaccinated first; d) a second AHP asking respondents to rate the importance of seven criteria that where "number of inhabitants", "number of daily COVID-19 deaths", "number of intensive care unit (ICU) beds per 100k population", "number of vaccines preordered", "annual income per head (GDP)", "investment in vaccine research and development (R&D)", and "vaccine production capacity". To control for potential biases, respondents were asked whether or not they have already been vaccinated (or waiting to receive one soon), to what extend COVID-19 had a negative impact on their lives, and also their Social Desirability (SD) tendency (*13*) (*for survey and instrument details see supplementary material*).

Results

Figure 1 provides a results overview of the study. There are noticable similarities between these results, mostly indicating that the majority of the general public has a tendency towards utilitarianism. When asked about their willingness to wait for 3 months to receive their own vaccine, respondents in both countries expressed the strongest agreement to wait for people in countries with higher number of COVID-19 deaths or fewer ICU beds to be vacciniated first.

Fig. 1. Survey results in Germany (DE) and the U.S. (US) in June 2021.

This tendency can also be observed within the results from the first AHP model where the four principles are compared. Here, "medical urgency" received 49.35% and 37.35% of German and the U.S. participants weighting, respectively. This utlitarian view was followed by egaliaterinsm being the second highly rated principle. This is particularly reflected in "equal access" receiving 32.69% of the U.S. and 25.35% of the German (DE) respondents' overall

weighting across the four principles. Participants in both Germany and the U.S. allocated more than half of the available vaccine doses to the country that had a closer similarity to a LMIC (Country B in Figure 1), even when the veil of ignorance was removed and they were asked to imagine themselves or one of their own vulnerable family members waiting for the vaccine. Following each step of this experiment, respondents were also asked if they would like to leave a comment explaining the reason behind their decision and their line of thoughts. These comment were consistently in line with how the respondents divided the 100 Million vaccine doses between the two countries during the previous steps. While there were general similarities across these comments, a few stood out: "*Even if the elderly person had to wait a bit, in Country A s/he almost certainly has sufficient family and societal resources to remain safe while waiting*", "*My family member does not outweigh the needs of the other country*", "*The number of cases and deaths should be one of the primary drivers for vaccine distribution if world public health is goal. As it should be*".

It is worth noting that out of the main principles addressed, "free market rules" received a relatively higher weighting by U.S. respondents than by those in Germany. The underlying components of these tendencies, however, become more apparent when the principles (first AHP) are compared with the criteria (second AHP; Figure 2). Of those reflecting a liberatarin view, in both countries, GDP was the least important ground – whereas "number of deaths" followed by "number of ICU beds" receiving the highest weightings in both countries.

Fig. 2. Weighting of 4 principles (inner circle) versus 7 criteria (outer circle): on both accounts, the public gave the utilitarian reasoning higher priority.

Table 1 shows the highest and lowest levels of priorities across the different survey modules. Some difference of opinion arise when it comes to valuing preordering more vaccines versus investment in R&D and having production capacity that are reflection of "merits". Nevertheless, utilitarian and egalitarian principles are given the highest priority no matter in what format the questions were asked.

Table 1. Ranking order of distribution schemes across three different survey modules.

AHP Principles		Item-scale		AHP Criteria	
DE	US	DE	US	DE	US
Medical Urgency	Medical Urgency	COVID-19 deaths	COVID-19 deaths	COVID-19 deaths	COVID-19 deaths
Equal Access	Equal Access	ICU beds	ICU beds	ICU beds	ICU beds
Production	Free Market	Inhabitants	Inhabitants	Inhabitants	Inhabitants
Free Market	Production	Production	R&D	Production	Production
		R&D	Preorder	Preorder	R&D
		Preorder	Production	R&D	Preorder
		GDP	GDP	GDP	GDP

Interpretations

The presented results connect very strongly to current discussions initiated – among others – by the multilateral organizations like the IMF, the Worldbank and the WHO. As for example presented in the July World Economics Outlook, global economic recovery hinges very strongly on vaccine distribution issues; the current distribution imbalances are found to trigger further and severe economic imbalances from a global perspective (*14*). From a different public health angle, WHO is raising attention towards growing disparities as HICs proceed towards third booster vaccine shots, whereas many LMICs are still struggling to access and distribute first and second COVID-19 vaccine doses ((*15*), p. 63). Such growing disparities are a major concern to the global public discourse – but actually, they should not be subject to policies at all but out joint commitment to avoid such developments and situations. If we think of humanity as one population, we are steering towards a situation where a large share of the population is vaccinated and a large share is not. This is a critical phase of the pandemic because it provides ideal conditions for SARS-Cov-2 to escape the vaccine and to emerge stronger than before through mutation and virus variants (*16*). Therefore, the pandemic will not be over before it is over everywhere on the globe. Public perceptions regarding distribution of COVID-19 vaccine doses that we report in this study are very much in line with this view of humanity as one population – which is both, an expression of fairness and arguably the best way out of the pandemic. Unfortunately, the actions of HICs are not in line with this expressed opinion of the general public. We are now in a situation where there are more vaccine doses available than people willing to be vaccinated in HICs – and the opposite in LMICs (*17*); which is both, shortsighted and against the preferences of the general public. Aligning public action in HICSs with these public perceptions might go a long way in overcoming the pandemic and valuing the view of the people at the same time.

References

1. J. Cohen, Countries now scrambling for COVID-19 vaccines may soon have surpluses to donate. *Science* (2021), doi:10.1126/science.abh4476.

2. L. M. Herzog, O. F. Norheim, E. J. Emanuel, M. S. McCoy, Covax must go beyond proportional allocation of covid vaccines to ensure fair and equitable access. *The BMJ*. **372** (2021), doi:10.1136/bmj.m4853.

3. E. J. Emanuel *et al.,* An ethical framework for global vaccine allocation. *Science*. **369**, 1309–1312 (2020), doi:10.1126/SCIENCE.ABE2803.

4. Our World in Data, *Coronavirus (COVID-19) Vaccinations* (2021) (available at https://ourworldindata.org/covid-vaccinations).

5. A. Mullard, How COVID vaccines are being divvied up around the world. *Nature* (2020), doi:10.1038/d41586-020-03370-6.

6. IHME, *COVID-19 Projections* (available at https://covid19.healthdata.org/global?view=daily-deaths&tab=trend); last accessed 06.08.2021.

7. B. Sen-Crowe, M. Sutherland, M. McKenney, A. Elkbuli, A closer look into global hospital beds capacity and resource shortages during the COVID-19 pandemic. *The Journal of surgical research*. **260**, 56–63 (2021), doi:10.1016/j.jss.2020.11.062.

8. A. Fontanet *et al.,* SARS-CoV-2 variants and ending the COVID-19 pandemic. *The Lancet*. **397**, 952–954 (2021), doi:10.1016/S0140-6736(21)00370-6.

9. GISAID, *Tracking of Variants* (2021) (available at https://www.gisaid.org/hcov19-variants/); last accessed 06.08.2021.

10. I. T. Katz, R. Weintraub, L.-G. Bekker, A. M. Brandt, From vaccine nationalism to vaccine equity - finding a path forward. *New England Journal of Medicine*. **384**, 1281–1283 (2021), doi:10.1056/nejmp2103614.

11. K. Ferguson, A. Caplan, Love thy neighbour? Allocating vaccines in a world of competing obligations. *Journal of Medical Ethics* (2020), doi:10.1136/medethics-2020-106887.

12. J. D. Moreno-Ternero, J. E. Roemer, The veil of ignorance violates priority. *Economics and Philosophy*. **24**, 233–257 (2008), doi:10.1017/S026626710800182X.

13. R. D. Hays, T. Hayashi, A. L. Stewart, A five-item measure of socially desirable response set. *Educational and Psychological Measurement*. **49**, 629–636 (1989), doi:10.1177/001316448904900315.

14. Gita Gopinath, *IMF World Economic Outlook July 2021: Vaccine differences drive economic differences* (available at https://blogs.imf.org/2021/07/27/drawing-further-apart-widening-gaps-in-the-global-recovery/); last accessed 06.08.2021.

15. The Independent Panel on Pandemic Preparedness and Response, *COVID-19: COVID-19: Make it the Last Pandemic* (GENEVA, 12 May 2021).

16. J. R. Mascola, B. S. Graham, A. S. Fauci, SARS-CoV-2 viral variants - tackling a moving target. *JAMA*. **325**, 1261–1262 (2021), doi:10.1001/jama.2021.2088.

17. J. S. Solís Arce *et al.,* COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. *Nature Medicine* (2021), doi:10.1038/s41591-021-01454-y.

Funding: There are no specific funding sources to report.

Author contributions: All authors contributed equally.

Competing interests: Authors declare that they have no competing interests.

Supplementary materials are included in a separate file regarding further sample characteristics and detailed analysis. All data for the survey is available upon request from the authors due to confidentiality reasons.